UPLOAD Filing
Coya Therapeutics, Inc.
Date: March 19, 2026 · CIK: 0001835022 · Accession: 0000000000-26-002775
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-294315
Letter
Re: Coya Therapeutics, Inc. Registration Statement on Form S-3 Filed March 16, 2026 File No. 333-294315 Dear Arun Swaminathan:
March 19, 2026
Arun Swaminathan Chief Executive Officer Coya Therapeutics, Inc. 5850 San Felipe St. Suite 500 Houston, TX 77057
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Perry Laub
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> March 19, 2026 Arun Swaminathan Chief Executive Officer Coya Therapeutics, Inc. 5850 San Felipe St. Suite 500 Houston, TX 77057 Re: Coya Therapeutics, Inc. Registration Statement on Form S-3 Filed March 16, 2026 File No. 333-294315 Dear Arun Swaminathan: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Perry Laub </TEXT> </DOCUMENT>